Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Dyslipidemia is a major risk factor for cardiovascular (CV) disease - the primary cause of death, worldwide. Although reducing levels of low-density lipoprotein-cholesterol can significantly reduce CV risk, a high level of residual risk persists, especially in people with obesity-related conditions, such as metabolic syndrome and type 2 diabetes mellitus. Peroxisome proliferator-activated recep...

Peroxisome Proliferator-Activated Receptor

Peroxisome proliferator - activated receptor

The peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. The discovery of PPARγ as a target of multimodal insulin sensitizers has attracted remarkable scientific interest and had a great impact on the pharmaceutical industry. Thi...

Peroxisome Proliferator-Activated Receptor

The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

Although peroxisome proliferator-activated receptor agonists are prescribed to improve cardiovascular risk factors, their cardiovascular safety is controversial. We therefore reviewed the literature to identify landmark randomized controlled trials evaluating the effect of peroxisome proliferator-activated receptor gamma agonists (pioglitazone and rosiglitazone), alpha agonists (fenofibrate and...